WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H525139
CAS#: 524-30-1
Description: Fraxin is a glucoside of fraxetin, an O-methylated coumarin. Fraxin was administered orally to rats to investigate its metabolism.
Hodoodo Cat#: H525139
Name: Fraxin
CAS#: 524-30-1
Chemical Formula: C16H18O10
Exact Mass: 370.09
Molecular Weight: 370.310
Elemental Analysis: C, 51.89; H, 4.90; O, 43.21
Synonym: Fraxin; Fraxetin-8-O-glucoside.
IUPAC/Chemical Name: 2H-1-Benzopyran-2-one, 8-(beta-D-glucopyranosyloxy)-7-hydroxy-6-methoxy-
InChi Key: CRSFLLTWRCYNNX-QBNNUVSCSA-N
InChi Code: InChI=1S/C16H18O10/c1-23-7-4-6-2-3-9(18)25-14(6)15(11(7)20)26-16-13(22)12(21)10(19)8(5-17)24-16/h2-4,8,10,12-13,16-17,19-22H,5H2,1H3/t8-,10-,12+,13-,16+/m1/s1
SMILES Code: COc1cc2ccc(=O)oc2c(c1O)O[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | Fraxin shows its antioxidative effect through inhibition of cyclo AMP phosphodiesterase enzyme. |
| In vitro activity: | The results of the in vitro study conducted in HepG2 cells indicated that the CCl4-induced changes were significantly ameliorated by pretreatment of fraxin. Moreover, immunohistochemistry staining and western blot assay demonstrated that pretreatment with fraxin can down-regulate CCl4-induced protein expression of MAPKs, NF-κB and COX-2. Overall, these studies indicate that fraxin exhibits hepatoprotective effect against CCl4-induced liver damage by reducing inflammation response, suppressing oxidative stress and lipid peroxidation and enhancing antioxidant activity. Reference: Biomed Pharmacother. 2017 Nov;95:1091-1102. https://pubmed.ncbi.nlm.nih.gov/28922728/ |
| In vivo activity: | 32 Sprague Dawley male rats were divided into 4 groups. The groups were organized as follows; sham, IR, IR + fraxin 10 mg/kg, and IR + 50 mg/kg fraxin groups. It was detected that the oxidant and proinflammatory markers increased and antioxidant parameters decreased in IR group but the results significantly reversed in treatment groups compared to IR group. Reference: Life Sci. 2020 Feb 1;242:117217. https://pubmed.ncbi.nlm.nih.gov/31884094/ |
| Solvent | Max Conc. mg/mL | Max Conc. mM | |
|---|---|---|---|
| Solubility | |||
| DMSO | 124.7 | 336.66 | |
| DMF | 50.0 | 135.02 | |
| PBS (pH 7.2) | 2.0 | 5.40 |
The following data is based on the product molecular weight 370.31 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | 1. Niu X, Liu F, Li W, Zhi W, Yao Q, Zhao J, Yang G, Wang X, Qin L, He Z. Hepatoprotective effect of fraxin against carbon tetrachloride-induced hepatotoxicity in vitro and in vivo through regulating hepatic antioxidant, inflammation response and the MAPK-NF-κB signaling pathway. Biomed Pharmacother. 2017 Nov;95:1091-1102. doi: 10.1016/j.biopha.2017.09.029. Epub 2017 Sep 14. PMID: 28922728. 2. Chang BY, Jung YS, Yoon CS, Oh JS, Hong JH, Kim YC, Kim SY. Fraxin Prevents Chemically Induced Hepatotoxicity by Reducing Oxidative Stress. Molecules. 2017 Apr 6;22(4):587. doi: 10.3390/molecules22040587. PMID: 28383514; PMCID: PMC6154468. 3. Topdağı Ö, Tanyeli A, Akdemir FNE, Eraslan E, Güler MC, Çomaklı S. Preventive effects of fraxin on ischemia/reperfusion-induced acute kidney injury in rats. Life Sci. 2020 Feb 1;242:117217. doi: 10.1016/j.lfs.2019.117217. Epub 2019 Dec 26. PMID: 31884094. 4. Li W, Li W, Yu J, Liu F, Zang L, Xiao X, Zhao J, Yao Q, Niu X. Fraxin inhibits lipopolysaccharide-induced inflammatory cytokines and protects against endotoxic shock in mice. Fundam Clin Pharmacol. 2020 Feb;34(1):91-101. doi: 10.1111/fcp.12500. Epub 2019 Aug 28. PMID: 31325387. |
| In vitro protocol: | 1. Niu X, Liu F, Li W, Zhi W, Yao Q, Zhao J, Yang G, Wang X, Qin L, He Z. Hepatoprotective effect of fraxin against carbon tetrachloride-induced hepatotoxicity in vitro and in vivo through regulating hepatic antioxidant, inflammation response and the MAPK-NF-κB signaling pathway. Biomed Pharmacother. 2017 Nov;95:1091-1102. doi: 10.1016/j.biopha.2017.09.029. Epub 2017 Sep 14. PMID: 28922728. 2. Chang BY, Jung YS, Yoon CS, Oh JS, Hong JH, Kim YC, Kim SY. Fraxin Prevents Chemically Induced Hepatotoxicity by Reducing Oxidative Stress. Molecules. 2017 Apr 6;22(4):587. doi: 10.3390/molecules22040587. PMID: 28383514; PMCID: PMC6154468. |
| In vivo protocol: | 1. Topdağı Ö, Tanyeli A, Akdemir FNE, Eraslan E, Güler MC, Çomaklı S. Preventive effects of fraxin on ischemia/reperfusion-induced acute kidney injury in rats. Life Sci. 2020 Feb 1;242:117217. doi: 10.1016/j.lfs.2019.117217. Epub 2019 Dec 26. PMID: 31884094. 2. Li W, Li W, Yu J, Liu F, Zang L, Xiao X, Zhao J, Yao Q, Niu X. Fraxin inhibits lipopolysaccharide-induced inflammatory cytokines and protects against endotoxic shock in mice. Fundam Clin Pharmacol. 2020 Feb;34(1):91-101. doi: 10.1111/fcp.12500. Epub 2019 Aug 28. PMID: 31325387. |
1: Yasuda T, Fukui M, Nakazawa T, Hoshikawa A, Ohsawa K. Metabolic fate of fraxin administered orally to rats. J Nat Prod. 2006 May;69(5):755-7. PubMed PMID: 16724835.
